Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells.

Borriello A, Caldarelli I, Bencivenga D, Cucciolla V, Oliva A, Usala E, Danise P, Ronzoni L, Perrotta S, Della Ragione F.

Carcinogenesis. 2011 Jan;32(1):10-8. doi: 10.1093/carcin/bgq211. Epub 2010 Oct 15.

PMID:
20952511
2.

Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.

Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.

Clin Cancer Res. 2009 Mar 1;15(5):1686-97. doi: 10.1158/1078-0432.CCR-08-2141. Epub 2009 Feb 24.

3.

BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.

Andreu EJ, Lledó E, Poch E, Ivorra C, Albero MP, Martínez-Climent JA, Montiel-Duarte C, Rifón J, Pérez-Calvo J, Arbona C, Prósper F, Pérez-Roger I.

Cancer Res. 2005 Apr 15;65(8):3264-72.

5.

Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.

Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.

Clin Cancer Res. 2006 Oct 1;12(19):5869-78.

6.

Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.

Scappini B, Gatto S, Onida F, Ricci C, Divoky V, Wierda WG, Andreeff M, Dong L, Hayes K, Verstovsek S, Kantarjian HM, Beran M.

Cancer. 2004 Apr 1;100(7):1459-71.

7.

Important therapeutic targets in chronic myelogenous leukemia.

Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.

Clin Cancer Res. 2007 Feb 15;13(4):1089-97. Review.

8.

Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.

Simara P, Stejskal S, Koutna I, Potesil D, Tesarova L, Potesilova M, Zdrahal Z, Mayer J.

Am J Hematol. 2013 May;88(5):385-93. doi: 10.1002/ajh.23419. Epub 2013 Mar 27.

9.

Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.

Majsterek I, Sliwinski T, Poplawski T, Pytel D, Kowalski M, Slupianek A, Skorski T, Blasiak J.

Mutat Res. 2006 Jan 31;603(1):74-82. Epub 2006 Jan 4.

PMID:
16388976
10.

BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.

Hentschel J, Rubio I, Eberhart M, Hipler C, Schiefner J, Schubert K, Loncarevic IF, Wittig U, Baniahmad A, von Eggeling F.

Int J Oncol. 2011 Sep;39(3):585-91. doi: 10.3892/ijo.2011.1062. Epub 2011 Jun 1.

PMID:
21637917
11.

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.

Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F, Belanger C, Manley PW, Leroy C, Etienne G, Roche S, Pasquet JM.

Cancer Res. 2008 Dec 1;68(23):9809-16. doi: 10.1158/0008-5472.CAN-08-1008.

12.

Differential tyrosine phosphorylation of leukemic cells during apoptosis as a result of treatment with imatinib mesylate.

Park J, Kim S, Oh C, Yoon SS, Lee D, Kim Y.

Biochem Biophys Res Commun. 2005 Oct 28;336(3):942-51.

PMID:
16157305
13.

Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.

Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ.

Clin Cancer Res. 2004 Oct 1;10(19):6661-8.

14.

PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.

Gontarewicz A, Balabanov S, Keller G, Panse J, Schafhausen P, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.

Leuk Res. 2008 Dec;32(12):1857-65. doi: 10.1016/j.leukres.2008.04.012. Epub 2008 Jun 2.

PMID:
18514829
15.

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.

Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, Rossi F, Gianazza E, Brueggen J, Cozens R, Pioltelli P, Pogliani E, Corneo G, Formelli F, D'Incalci M.

J Natl Cancer Inst. 2000 Oct 18;92(20):1641-50.

16.

Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.

Okabe S, Tauchi T, Ohyashiki K.

Clin Cancer Res. 2008 Oct 1;14(19):6181-6. doi: 10.1158/1078-0432.CCR-08-0461.

17.

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.

Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG.

J Hematol Oncol. 2011 Feb 7;4:6. doi: 10.1186/1756-8722-4-6.

18.

Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.

Koyama N, Koschmieder S, Tyagi S, Portero-Robles I, Chromic J, Myloch S, Nürnberger H, Rossmanith T, Hofmann WK, Hoelzer D, Ottmann OG.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2025-31.

19.

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ.

Cancer Res. 2005 Jun 1;65(11):4500-5.

Supplemental Content

Support Center